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Formulation process is a very complex activity which sometimes implicates taking decisions about parameters or variables to
obtain the best results in a high variability or uncertainty context. Therefore, robust optimization tools can be very useful for
obtaining high quality formulations. This paper proposes the optimization of diﬀerent responses through the robust Taguchi
method. Each response was evaluated like a noise variable, allowing the application of Taguchi techniques to obtain a response
under the point of view of the signal to noise ratio. A L18 Taguchi orthogonal array design was employed to investigate the
eﬀect of eight independent variables involved in the formulation of alginate-Carbopol beads. Responses evaluated were related
to drug release profile from beads (t50% and AUC), swelling performance, encapsulation eﬃciency, shape and size parameters.
Confirmation tests to verify the prediction model were carried out and the obtained results were very similar to those predicted in
every profile. Results reveal that the robust optimization is a very useful approach that allows greater precision and accuracy to the
desired value.
1. Introduction
The use of natural polymers for the design of drug delivery
systems has long been the subject of great interest during
the past decades. Sodium alginate is a sodium salt of alginic
acid, a naturally occurring nontoxic polysaccharide found in
marine brown algae. Alginate has been widely used as food
and pharmaceutical additives, such as tablet disintegrant,
thickening, and suspending agent. It contains two uronic
acids, α-L-guluronic (G) and β-D-mannuronic acids (M),
and is composed of homopolymeric blocks and blocks
with an alternating sequence [1]. This polymer can form a
reticulated structure when it contacts with Ca2+ and thus
it has been used to produce sustained release particulate
systems for various drugs, proteins, and even cells [2–4].
Gelation occurs by an ionic interaction between the calcium
ions and the carboxylate anions of G-G blocks as calcium
ions diﬀuse from the external source into the droplet forming
a polyanionic microcapsule.
The addition of a polycation (poly-L-lysine or chitosan)
to the gelation medium induces the formation of polyan-
ionic-polycationic complexes, which stabilizes the ionic gel
network and reduces the alginate permeability [5, 6].
The main advantage of using alginate to encapsulate
drugs is that the alginate gelation process occurs under very
mild conditions without using high temperatures or chemi-
cal crosslinking agents. Another advantage of using alginate
is that the alginate gel can also be converted to sol by adding
chelating agents, such as Na+ and EDTA. However, the drug
releasing properties of Ca-sodium alginate matrices suﬀer
from some serious problems. Firstly, the drugs could be
leaked during the gel formation due to the long immersion
time, which decreased the encapsulation eﬃciency. Secondly,
the burst release of the drugs from pure Ca-sodium alginate
beads is severe due to the quick breakdown of beads in the in
vitro release process. Currently, much eﬀort has been made
for improving the performance of Ca-sodium alginate beads
as drug delivery carriers.
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Table 1: Some of the factors aﬀecting the encapsulation process of drugs into alginate beads.
Factor Drug Eﬀect Reference
Related with the formulation
Gliclazide
Alginate concentration
+ EE
+ diameter
−porosity
[7]
−release rate
+ swelling
BSA + EE [5, 8]
Glucose
Volume of the alginate
solution
Gliclazide −diameter [7]
Divalent cation
concentration
BSA
−EE [5, 8, 9]VEGF
Glucose
Crosslinker/alginate ratio
Neutral (xanthan
gums, ethylcellulose,
PVA)
Diclofenac sodium
+ EE
[10, 11]
+ swelling
Cationic (chitosan, poli-L-lysine)
Proteins
Oligonucleotides
+ EE [3, 5, 12]
Waxy compounds (Compritol 888 ATO, Precirol ATO
5, Gelucires, glyceryl palmitostearate, magnesium
aluminum silicate)
Tamsulosin,
diclofenac sodium
+ EE
−release rate
[13–16]Anionic (CMC,
Eudragit L100,
dextran sulphate) and
cationic
Insulin
+EE
+ diameter
−release rate
Surfactant presence Gliclazide −diameter
[7]
+ EE
Related with the process
Needle size BSA −diameter [5]
Coaxial air volume BSA −diameter [5]
Drying process BSA [5]
Stirring rate Gliclazide
−EE
[7]
−diameter
Therefore, many factors are involved in the formulation
of alginate microspheres. Some of them are summarized in
Table 1.
Drug release from calcium-alginate beads depends on
the swelling of the beads and the diﬀusion of the drug
in the gel matrix [17]. Although alginate beads do not
swell appreciably in acidic fluid [18], the beads swell and
erode/disintegrate rapidly in the intestinal fluid, leading to
a quick release of the loaded drug within a few minutes
[6, 19] and hence calcium alginate matrix alone does not
seem suitable as an oral controlled release system [20].
Polymeric materials have been widely used in order to
conveniently modify and modulate the drug release from
controlled-release microparticles. However, a large number
of factors, including the chemical-physical properties of the
raw materials (both drug and excipients), the composition
and the relative amounts of the components in the formula-
tions, as well as the manufacturing process parameters, can
influence the drug release behavior from the final products
[6, 7, 21, 22].
In the present study, we attempted to reinforce calcium-
alginate beads containing methylene blue as a model drug
by incorporating Carbopol 940 as hydrophilic polymer. This
is a poly acrylic acid in anionic form that contains many
free hydroxyl groups. Since it can form a gel, it has been
used in combination with other polymers to control the drug
release.
There are previous reports about the eﬀect of carbomers
on characteristics of calcium-alginate beads [23, 24] but not
for Carbopol 940. Therefore, we intended to investigate the
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eﬀect of this hydrophilic and swelling polymer on release
behavior of calcium-alginate beads.
The preparation of calcium-alginate beads for drug en-
trapment is a stepwise procedure. The industrial experimen-
tation includes a great number of parameters and a full
factorial design that yield large number of experiments. Con-
ventional optimization procedures involve altering one inde-
pendent factor at a time keeping all others remain constant,
which enables to assess the impact of those particular param-
eters on the process performance. These procedures are time
consuming and cumbersome because require more exper-
iments and cannot provide information about the mutual
interactions of the parameters [25]. To reduce these numbers
of experiments, a small set of trials with all possible combi-
nations is selected by using various statistical tools [26].
Statistical experimental design methods, such as the
fractional factorial design [8], the Plackett-Burman method
[27], response surface methodology [28], the Box-Behnken
design [29, 30], and the Taguchi method [31], provide a
systematic and eﬃcient plan for experimentation to achieve
certain goals so that many control factors can be simultane-
ously studied. In contrast to the traditional “one-factor at
a time” approach, these methods can be used to examine
and optimize the operational variables while considering the
interactive eﬀects among the control factors.
The Taguchi method focuses on product robustness
against uncontrollable influences, or noise. The method is
designed to reduce variability, and optimize function or per-
formance with the lowest cost components. Taguchi method
of orthogonal array design of experiment (DOE) involves the
study of any given system by a set of independent variables
(factors) over a specific region of interest (levels). This
approach also facilitates to identify the influence of individ-
ual factors, and establish the relationship between variables
and operational conditions. In this methodology, the desired
design is sought by selecting the best performance under
conditions that produce consistent performance [32] and the
results from small-scale experiments are valid over the scale
up schedule [33].
Robustness is essential in the production of nearly all
products. The variation in the quality of the product may
follow from environmental factors and/or manufacturing
variables that cannot be easily controlled (noise factors). In
addition to emphasizing that the variability in the quality of
the product and factors interactions should be reduced [34],
the Taguchi method uses the signal-to-noise ratio (S/N),
which is directly transformed from the quadratic quality
loss function, as a measure to determine the robustness of a
process. Thus, optimizing process parameters by the Taguchi
method is an attempt not only to bring the average quality
near to the target value, but also to simultaneously minimize
the variation in quality [35]. Therefore, this method has been
extensively applied in industry and its application caused
significant changes in several industries, in manufacturing
processes and total quality control [36–38].
This technique is somehow not very well known for
optimization of pharmaceutical processes. This paper oﬀers a
rapid and eﬃcient methodology to study and optimize phar-
maceutical formulations, based on the Taguchi orthogonal
array design. To do this, as an example, we used alginate-
Carbopol beads formulated by ionotropic gelation with
methylene blue (MB) as hydrophilic drug model.
After the selection of noise and control factors, we se-
lected the profiles (responses) to optimize with the aim
to demonstrate the applicability of this methodology in
the optimization of diﬀerent profiles such as drug release,
swelling rate, or the morphology of the beads. Afterward,
the experimental design and data analysis procedure, we
selected the best profiles for Taguchi optimization and then
we compared the results with predicted ones by lineal
regression. Finally we compared the accuracy of the opti-
mization.
2. Materials andMethods
2.1. Materials. Sodium alginate (viscosity 2% w/v: 250 cP)
and triethanolamine (TEA) were purchased from Sigma
Aldrich. Calcium chloride (Panreac, Spain) was selected as
cation donor salt. MB was used as hydrophilic drug model.
Carbopol 940 (Acofarma, Spain) was added to control the
drug release from the alginate beads. Sodium tripolyphos-
phate and Tris(hydroxymethyl) aminomethane (TRIS) were
obtained from Sigma (Spain).
2.2. Preparation of Beads. The beads were prepared by fol-
lowing the extrusion/precipitation method [39, 40]. Briefly,
a sodium alginate aqueous solution containing 0.01% (w/v)
MB and 2% (w/v) of sodium alginate was prepared by a
simple mixing step. Carbopol 940 was dispersed in purified
water and then was added to the above solution. As a
function of the experiment, TEA was added to this solution.
The beads were prepared by dropping the alginate-Carbopol
solution (50mL) containing MB from a syringe using a
perfusion pump (Perfusor fm, Braun), through a 0.9mm
diameter needle into a gently stirred 0.25M calcium chloride
aqueous solution (IKA Eurostar). Diﬀerent concentrations of
Carbopol, at diﬀerent dropping rate and stirring rates were
used, as was reported in Table 2. The obtained hydrogels were
maintained into the calcium chloride solution for diﬀerent
time periods to complete the chemical reaction. The beads
were collected by decanting the calcium chloride solution,
washed with deionized water and dried to a constant weight.
At this stage, diﬀerent drying methods were used: room
temperature (20◦C), rotary evaporator (reduced pressure,
vacuum and 80◦C), or oven (100◦C).
2.3. Characterization of Beads
2.3.1. Entrapment Eﬃciency. TheMB content in the dry sam-
ples was determined by dissolving the beads, previously
weighed, in a tripolyphosphate solution (0.03M; 100mL).
The resulting solution was filtered and the drug concen-
tration was analyzed by UV spectrophotometry, at 664 nm,
using a UV-visible spectrophotometer (Hitachi U-2000).
Entrapment eﬃciency was calculated as the percentage (w/w)
of the theoretical drug content. Results were based on tripli-
cate determinations.
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Table 2: Factors and their corresponding levels implemented for the construction of L18 orthogonal array.
Factor
Levels used, actual (coded)
Low (−1) Medium (0) High (+1)
Independent variables
A: addition of TEA No Yes
B: concentration of Carbopol (% w/v) 1 2 4
C: flux rate of polymeric solution (mL/min) 1 2 3
D: stirring rate of stirrer (rpm) 100 300 500
E: reaction time of beads into CaCl2 solution (min) 5 30 60
F: drying method Room Rotary evaporator Oven
G: NaCl (% w/v) 0 0.01 0.1
H: pH 7.2 7.6 8.0
2.3.2. In Vitro Drug Release Studies. The drug release profiles
of beads were determined using the USP 28 paddle method.
The dissolution medium was 900mL (sink conditions) of
Tris-buﬀer solution adjusted at diﬀerent pH and NaCl
concentration values as a function of the experiment. The
stirring speed was 50 rpm and the temperature was main-
tained at 37 ± 0.5◦C. Accurately weighed samples of 700mg
beads were used for the test. At selected time intervals for
a period of 420min, aliquots each of 3mL were withdrawn
from de dissolution medium through a 0.45 μm membrane
filter and replaced with an equivalent amount of the fresh
dissolution medium. Concentrations of MB were then spec-
trophotometrically determined at 664 nm. Each experiment
was carried out in triplicate and the results were averaged.
Tris-buﬀer solution was selected as the dissolution
medium because in the formation of alginate gel, alginate
reaction with calcium ions turns reversible with sodium ions,
and a disaggregation of the beads occurs [6]. We selected
this buﬀer to control swelling process by modifying NaCl
concentration.
2.3.3. Swelling Process. The amount of absorbed water was
determined following described methods by many authors
[7, 41, 42]. In a first stage, a certain number of beads,
accurately weighed (W0), were placed in glass beakers
containing 80mL of tris-buﬀer and NaCl concentration set
by DOE. Next, the glass beakers were placed in a thermostatic
bath at 25◦C and 150 rpm. At time intervals of 1 h, beads were
filtered and weighed (We).
Swelling percentage (Esw) was calculated using the fol-
lowing expression [43]:
ESW =
[
We −W0
W0
]
× 100, (1)
where We is the wet weight of beads and W0 is the initial
weight of beads.
2.3.4. Morphological Properties of Beads. Morphological
characteristics of beads were observed by Scanning Electron
Microscopy, SEM (Philips XL30). The samples were sputter-
coated with Au/Pd using a vacuum evaporator (Edwards)
and examined at 20 kV accelerating voltage.
The size and shape of the beads were determined using
image analyzer software (Image Pro Plus). The length and
breadth were measured from the digital images of each
bead and its size calculated from the average of these two
dimensions [44].
For each formulation, 30 beads were randomly selected
for measurement; the results were then averaged.
2.4. Optimization Methodology. Optimization methodology
adopted in this study was divided into four phases (with var-
ious steps): planning, performance, analysis, and validation.
The schematic representation of the designed methodology
was depicted in Figure 1 (modified from [34]).
2.4.1. Phase I. Planning
(1) Defining the Problem and the Goal. First step in Phase I is
to determine the factors to be optimized in the production
and characterization of alginate-Carbopol beads that have
critical eﬀect on the drug release, encapsulation eﬃciency,
and in the morphological properties of the beads. The goal
is to evaluate the eﬀect of diﬀerent factors on the elaboration
of the beads and to obtain the perfect combination between
the levels of the factors to optimize theirs properties.
(2) Identifying the Factors to Be Optimized. Six process
parameters (flux rate, stirring rate, incubation time, drying
mechanism, NaCl concentration, and pH of the dissolution
medium) and two formulation parameters (presence of TEA
and Carbopol concentration) were evaluated. The normal
practice is to experiment with the feasible range, so that the
variation inherent in the process does not mask the factors
eﬀects. The controls factor and theirs levels are exposed in
Table 2.
(3) Identifying the Test Conditions to Optimize. The respons-
es to be optimized from the characterization of alginate-
Carbopol beads are those that have critical eﬀect on the
drug release, encapsulation eﬃciency, and morphological
properties of the beads. Selected responses are exposed in
Table 3.
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Validation experiments
Phase I. Planning
Individual
factor
contribution
Relative
factor
interaction
Determination of
optimum levels for
factors
Establishment of best
optional conditions
for process optimization
Performance
under optional
conditions
Analyze the data using DOE pack 2000 software
Predict the performance at these levels
Identify the control factors and their levels
Design the experimental matrix
Define the data analysis procedure
Perform the designed experiments
Identify the factors to be optimized
Identify test conditions
Defining the problem and the objective
Phase II. Performance
Phase IV. Validation
Phase III. Analysis
Figure 1: Schematic diagram of the steps involved in the Taguchi methodology.
Table 3: Test conditions to optimize.
Profile analyzed Selected variable
Drug release
Time to release 50 percent of entrap-
ment drug (t50%)
Area under curve (AUC)
Entrapment eﬃciency Entrapment eﬃciency (EE)
Swelling performance Swelling rate (SR)
Shape of the particles Shape factor (SF)
Size of the particles Mean diameter (Dm)
(4) Experimental Design and Data Analysis Procedure. The
fundamental principle of the Taguchi method is to improve
the quality of a product byminimizing the eﬀect of the causes
of variation without eliminating the causes [45]. Threemajor
tools used in the Taguchi method are the orthogonal arrays,
analysis of variance (ANOVA), and the signal to noise ratio
(S/N).
The Taguchi approach provides an opportunity to select
a suitable orthogonal array depending on the number of con-
trol factors and theirs levels [46]. The orthogonal arrays give
equal credence to all the parameters being investigated while
ANOVA determines the contribution of each parameter in
the design of the experiment. This is a fractional factorial
approach and reduces the number of experiments.
Orthogonal array is a matrix of numbers arranged in
rows and columns. Each row represents the level of factors
in each run and each column represents a specific level for a
factor that can be changed for each run.
S/N ratio is an indicative of quality, and the purpose
of the Taguchi experiment is to find the best level for each
operating parameter to maximize the ratio [47]. Analysis
of the experimental data using the ANOVA and eﬀects of
the factors gives the output that is statistically significant for
finding the optimum levels.
In the Taguchi method, quality is measured by the
deviation of a characteristic from its target value, and a loss
function [L(y)] is estimated for the deviation as L(y) =
k×(y − m)2, where k denotes the proportionality constant,
m represents the target value and y is the experimental value
obtained for each trail. In case of bigger and better quality
characteristics, the loss function can be written as L(y) =
k × (1/y2) and the expected loss function can be represented
by:
E
[
L
(
y
)] = k · E
(
1
y2
)
, (2)
where E(1/y2) can be estimated from n number of samples
as:
∑n
i=1
[
1/y2i
]
n
. (3)
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In order to measure the quadratic loss function, the
Taguchi introduces the signal-to-noise (S/N) ratio for mea-
suring the quality through orthogonal array based experi-
ments. S/N ratios take into account both the variability in
the response data and the closeness of the average response
to a target value. The S/N ratio characteristics can be divided
into three categories when the variable is continuous [48]:
(i) nominal the best:
S
N
= −10 log
(
y2i
νyn
)
, (4)
(ii) smaller the better:
S
N
= −10 log
(∑
i y
2
i
n
)
, (5)
(iii) bigger the better:
S
N
= −10 log
(
1/
∑
i y
2
i
n
)
, (6)
where y is the average of observed data, n is the number of
observations, and yi the observed data for the ith run. In the
nominal best study, y and n are nominal values those are to
be achieved.
For each type of characteristics, with the above S/N ratio
transformation, the higher the S/N ratio, the better is the
result. The uncontrollable factors which cause the functional
characteristics of a product to deviate from their target values
are called noise factors. The overall aim of quality is to make
products that are robust with respect to all noise factors [49].
The design was performed by an L18 array. In the present
study, three levels of seven factors and two levels of one factor
(Table 2) were considered and the size of experimentation
was represented by symbolic array of L18 (which indicated
18 experimental trials) (Table 2). The three levels of all the
factors have been assigned (except TEA (21)), with a layout
of L18 (21 × 35).
2.4.2. Phase II. Performance of Experiments. After phase I,
in which the factors to be optimized, theirs levels and the
experimental matrix were selected, the experiments were
carried out by triplicate (Table 4) and the selected variables
were determined.
2.4.3. Phase III. Analysis of the Data and Optimization
(1) Analysis of Data. At this stage, a statistical analysis of
variance was performed to determine which test parameters
were statistically significant for every variable. Moreover, the
influence of each factor on the diﬀerent response variables
selected was determined.
(2) Optimization. After the analysis of the data, we pro-
ceeded to determine the optimal set parameter configura-
tion. Optimization process was made applying the marginal
means methodology (also called average rate or main eﬀects
analysis).
In order to do that, we obtained the average value of S/N
ratio of every variable in every level of response and then
the results were plotted in a graphic of marginal means. In
the Taguchi method, we always tried to maximize the S/N
ratio, so we select the levels with the higher values of S/N
ratio in every factor that give us themaximum S/N final ratio.
The diﬀerence in every response is the method followed for
the consecution of the S/N ratio, as it was explained before.
S/N ratios for every variable were obtained as Table 3 ex-
poses.
2.4.4. Phase IV. Validation Experiments. With S/N ratio and
ANOVA analysis, the optimal combination of the testing
parameters could be predicted for a 95% confidence level.
Also we can predict the future results that every combination
is going to obtain by regression of the main influencing
factors according to the ANOVA.
In order to validate this methodology, validation exper-
iments were further performed using the optimized condi-
tions obtained for each response and then the results will
be compared to the predicted by regression. If final results
are similar to the predicted, we could validate the proposed
methodology.
3. Results and Discussion
3.1. ANOVA. The application of the experimental design
methodology has the objective of identifying the most
significant factors influencing the formulation of alginate-
Carbopol beads containing a water-soluble drug, and estab-
lishing the best levels for optimizing diﬀerent response
variables.
Results obtained for these parameters, expressed as mean
values, are presented in Table 4. ANOVA could be used as
a tool for the detection of main eﬀects. Data reported
in Table 5 revealed that the release parameters (i.e., t50%
and AUC of release profiles) were significantly aﬀected
by Carbopol concentration and addition of TEA into the
polymeric solution. Also, the presence of TEA significantly
influenced on the entrapment eﬃciency and the particle size,
whereas the swelling percentage was also aﬀected by the
NaCl concentration into the dissolutionmedium. Finally, the
morphological parameters, expressed as shape factor, were
mainly aﬀected by the drying procedure and the stirring rate
applied from the stirrer apparatus.
Contribution degrees of each factor to every response
have been graphically showed in Figure 2. These findings will
be discussed in next sections.
3.1.1. Release Profiles: Time to Release 50% of Entrapment
Drug (t50%) and Area under the Curve (AUC). As shown
in Table 5, all factors except the NaCl concentration exert
significant influence on t50%. In the case of AUC, NaCl con-
centration neither pH had influence on this response. From
Figures 2(a) and 2(b), we can conclude that the Carbopol
concentration (factor B) had the most significant eﬀect on
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Table 4: Experimental layout using a L18 orthogonal array and results obtained in every run.
Run t50% AUC EE SR SF Dm
Mean S/N Mean S/N Mean S/N Mean S/N Mean S/N Mean S/N
1
A−1B−1C−1D−1 73.00 28.82 268.68 49.11 48.43 37.04 2863.78 69.14 0.52 −5.74 1.34 −2.71
E−1F−1G−1H−1
2
A−1B−1CoDo 50.00 27.96 421.78 49.29 54.88 38.26 1937.37 65.74 0.20 −13.88 1.47 −3.43
EoFoGoH0
3
A−1B−1C1D1 69.33 35.57 117.23 48.60 53.63 38.08 1320.67 62.42 0.25 −12.06 1.53 −3.70
E1F1G1H1
4
A−1BoC−1D−1 91.33 31.94 461.89 48.23 54.88 38.17 1681.62 64.51 0.58 −4.77 1.72 −2.96
EoFoG1H1
5
A−1BoCoDo 102.33 32.18 405.74 48.66 59.00 38.92 2177.52 66.76 0.27 −11.32 1.64 −4.50
E1F1G−1H−1
6
A−1BoC1D1 198.33 25.60 348.62 47.04 53.51 38.08 1119.52 60.98 0.65 −3.83 1.69 −4.61
E−1F−1GoH0
7
A−1B1C−1Do 118.67 19.17 354.48 48.22 54.34 38.21 1610.31 64.14 0.30 −10.47 1.51 −3.65
E−1F1GoH1
8
A−1B1CoD1 293.33 28.10 257.57 46.46 54.46 38.24 1082.83 60.69 0.25 −12.01 1.54 −3.73
EoF−1G1H−1
9
A−1B1C1D−1 106.00 18.80 427.85 47.90 57.14 38.65 1459.06 63.28 0.55 −5.26 1.66 −4.42
E1FoG−1H0
10
A1B−1C−1D1 60.00 24.77 448.50 48.89 59.73 39.04 2786.18 68.90 0.19 −14.68 2.07 −6.33
E1FoGoH−1
11
A1B−1CoD−1 82.67 22.18 634.32 48.71 59.33 38.97 1151.14 61.22 0.26 −11.95 1.83 −5.27
E−1F1G1H0
12
A1B−1C1Do 119.33 40.29 401.70 47.93 56.07 38.49 3685.23 71.32 0.55 −5.20 1.57 −3.97
EoF−1G−1H1
13
A1BoC−1Do 111.67 23.30 1326.03 47.92 58.83 38.91 1868.79 65.39 0.40 −9.30 1.73 −5.12
E1F−1G1H0
14
A1BoCoD1 148.67 36.17 225.15 47.45 59.88 39.06 3003.21 69.55 0.20 −13.88 1.72 −4.70
E−1FoG−1H1
15
A1BoC1D−1 209.33 36.72 469.47 47.14 59.49 39.00 2017.31 66.10 0.38 −8.50 1.56 −4.01
EoF1GoH−1
16
A1B1C−1D1 238.67 40.29 1052.68 46.04 53.97 38.15 3094.41 69.81 0.35 −9.26 1.67 −4.54
EoF1G−1H0
17
A1B1CoD−1 142.00 32.25 536.70 48.08 56.39 38.52 1554.57 63.83 0.34 −9.40 1.41 −3.04
E1F−1GoH1
18
A1B1C1Do 138.33 33.61 841.84 47.79 60.02 39.08 1420.16 63.05 0.26 −11.71 2.81 −8.99
E−1FoG1H−1
release characteristics. However, this eﬀect is positive in case
of t50% (97.11) and negative in case of AUC (−6316).
The influence of the Carbopol percentage on drug release
profile is due to the eﬀect of this polymer on the structure of
the beads, as was discussed by other authors [50]. The density
of the beads increases as the concentration of this polymer
increases, suggesting that the beads formed at higher con-
centrations are more compact and less porous than those
prepared at low polymer concentration [7]. The presence of
a higher network density in the structure has been demon-
strated by other authors in the preparation of Carbopol and
PVP microspheres [16, 50]. Moreover, taking into account
the swelling properties of this hydrophilic polymer, it is
confirmed that the presence of the gel layer thickness acts as
a barrier for the penetration medium thereby retarding the
diﬀusion of MB [7, 11].
All these contribute to produce a slowing in MB release
rate (increasing the t50%), making diﬃcult the output of the
drug to the dissolution medium (diminishing the AUC).
3.1.2. Entrapment Eﬃciency. According to ANOVA analysis,
the factor with higher contribution and statistical signifi-
cance on the entrapment capacity of the drug was the incor-
poration of TEA into formulations.
TEA is a weak base that ionizes carboxylic groups in the
chains of carbomers. As a result, the structure of the gel
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Table 5: ANOVA results: eﬀect of the variables on t50%, AUC, % entrapment (EE), swelling percentage (SR), shape factor (SF), and particle
size (DM).
Factors
t50% AUC EE
F-ratio P I-hat F-ratio P I-hat F-ratio P I-hat
A 89.52 <0.001 16.48 144.1 <0.001 −1892 11.2 0.004 5.57
B 2072 <0.001 97.11 1070 <0.001 −6316 0.27 0.607 1.07
C 132.5 <0.001 24.56 136 <0.001 −2252 1.41 0.25 2.42
D 564 <0.001 50.67 251.7 <0.001 −3063 0.003 0.955 −0.12
E 172.9 <0.001 −28.06 52.87 <0.001 1404 1.27 0.274 2.30
F 83.07 <0.001 −19.44 21.36 <0.001 892.2 2.18 0.157 3.01
G 0.01 0.918 −0.22 0.01 0.921 −19.4 0.67 0.425 1.66
H 213.4 <0.001 −31.17 3.20 0.082 345.2 0.53 0.474 −1.49
Factors
SR SF DM
F-ratio P I-hat F-ratio P I-hat F-ratio P I-hat
A 1842 <0.001 592 34.79 <0.001 −0.072 12.78 <0.001 0.255
B 1208 <0.001 −587.2 0.78 0.383 0.013 2.19 0.148 0.128
C 808.8 <0.001 −480.5 11.9 <0.001 0.051 2.19 0.148 0.130
D 274.4 <0.001 279.9 69.35 <0.001 −0.124 1.69 0.201 0.115
E 0.00 0.99 −0.22 4.49 0.041 −0.032 2.73 0.108 −0.142
F 62.8 <0.001 −133.9 100.4 <0.001 −0.149 0.80 0.377 0.077
G 5856 <0.001 −1293 23.4 <0.001 −0.072 8.78 0.005 0.261
H 25.09 <0.001 84.64 15.63 <0.001 0.059 8.15 0.007 −0.251
changes its conformation, going from a relaxed state in spiral
form to a rigid form, which provides viscosity and consis-
tency to the beads. This structural conformation increases
the entrapment eﬃciency. The same results have been ob-
tained by other authors when they added chitosan to the
alginate matrix to prepare beads [5].
Once the base was added, the increase of entrapment
eﬃciency is as consequence of the creation of a higher
network density and the electrostatic interaction between the
drug and the polymers [16]. At the end of the process, the
resulting beads become harder and thicker, favoring entrap-
ment eﬃciency inside the beads but making diﬃcult its later
release.
3.1.3. Swelling Percentage. After the ANOVA analysis, we can
determine that practically all factors have statistical influence
on this dependent variable. The factor presenting the higher
influence was NaCl concentration in the dissolution medium
followed by TEA addition and Carbopol concentration.
According to ANOM test for the factor NaCl concen-
tration (data not showed), the presence of sodium ions
acts hindering the swelling process. Swelling percentage will
increase as NaCl concentration decreases (I-hat = −1293).
This result can be explained on the basis of the swelling
mechanism of these polymeric structures alginate-Carbopol.
It is well accepted that the alginate beads in an aqueous
medium without sodium ions do not swell well, but when
these ions are present in themedium, the preformed complex
between the alginate and calcium turns unstable [51, 52].
This could be explained by the ionotropic phenomenon that
occurs between the Ca2+ ions of the alginate beads and the
Na+ ions present in release medium that finally produces a
capture of the Ca2+ by the chlorine ions. This fact produces
a disaggregation of the bead structure leading to erosion
and dissolution of the swollen beads and increasing the drug
release rate [5, 9, 51]. This can be appreciated in Figure 3,
where beads corresponding to batch 11 with higher NaCl
concentration have lower swelling percentage at the same
time than others.
In addition, TEA incorporation produces a rigid struc-
ture inside the beads and increase carboxylic groups with
negative charge. These groups have a high aﬃnity for water
molecules so more quantity of water can get inside the bead,
increasing the swelling of the beads in time and intensity.
These results were visualized by photographing the samples
during the swelling process tests. We can notice a higher
swelling in batches with TEA addition (Figure 4) than in
other lots without TEA at the same time.
3.1.4. Shape Factor. According to ANOVA analysis, the stir-
ring rate and the drying method of beads are the factors that
have the higher influence on this morphological parameter.
Stirring rate has an important statistical significance con-
cerning the shape and size parameters [7]. When alginate-
Carbopol drops fall into CaCl2 solution, stirring rate produce
a force that molds the final morphological aspect of the
beads, in relation to their shape and surface. As the stirring
rate increases, beads will be less spherical and more irregular
in its surface, which produces an increase of shape factor
and a decrease in its circularity (inverse of SF), as we can
demonstrate in Figure 5.
From the evaluation of the drying process, we must
keep in mind the characteristics of every treatment, because
they can aﬀect many properties of the beads [40]. Drying
The Scientific World Journal 9
B∗
D∗
H∗ E∗ C∗ A∗ F∗ G
×103
−5
5
15
25
35
45
55
65
75
85
95
SS
 fo
r
t 5
0%
(a)
B∗
D∗
A∗ C∗
E∗ F∗ H∗ G
−2.5E + 07
2.5E + 07
7.5E + 07
1.25E + 08
1.75E + 08
2.25E + 08
2.75E + 08
3.25E + 08
3.75E + 08
4.25E + 08
SS
 fo
r 
A
U
C
(b)
A∗
F C E G H B D
−100
0
100
200
300
400
500
SS
 fo
r 
E
E
(c)
G∗
A∗
B∗
C∗
D∗ F∗ H∗ E
(d)
F∗
D∗
A∗
G∗ H∗ C∗ E∗ B
−0.1
−0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
SS
 fo
r 
SF
(e)
A∗
G∗
H∗
E B C D
F
−0.4
−0.2
0
0.2
0.4
0.6
0.8
1
1.2
SS
 fo
r 
D
m
(f)
Figure 2: Scree plot obtained for the variables using the results of the ANOVA analysis. (a) Time to release 50% of entrapment drug, (b) area
under the curve, (c) entrapment eﬃciency, (d) swelling rate, (e) shape factor, and (f) Diameter medium. ∗Values with statistical significance
(α < 0, 01). A: TEA; B: Carbopol (% w/v); C: flux rate (mL/min); D: stirring rate (rpm); E: retention time (min.); F: drying method; G: NaCl
(% w/v); H: pH.
(a) (b) (c)
Figure 3: Digital images corresponding to samples during swelling tests (after 180 minutes). (a) batch 11 (0.1M NaCl), (b) batch 15 (0.01M
NaCl) and (c) batch 16 (without NaCl).
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(a) (b)
Figure 4: Digital images corresponding to samples during the swelling test. (a) Batch 17 (with TEA) and (b) batch 8 (without TEA).
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Figure 5: SEM images of alginate-Carbopol beads prepared with diﬀerent stirring rates (a) 100 rpm (batch 11) and (b) 500 rpm (batch 14).
technique could influence several bead characteristics such
as size [53–55], shape, mechanical properties [54], swelling
properties [54, 55], drug release kinetics [56] and even drug
migration to periphery of the beads along with water during
drying [53, 57].
When the beads were dried at environmental conditions,
the water evaporation is slow and progressive. This slow loss
of water allow the colloidal structure to settle slowly without
getting to fracture point, obtaining at the end more spherical
and smooth beads (Figure 6(a)).
During the oven process, the drying temperature was
about 100◦C and hence, heat energy was supplied to the sys-
tem, producing a strong and quick loss of water from the
beads. As a consequence, the shape was altered producing
roughs on the surface of the beads (Figure 6(b)).
When the gelled structures were yielded in a rotary evap-
orator, the process was submitted to 80◦C into a thermostatic
bath and applying vacuum. In this case, the evaporation
process is quicker than oven process even when we are
applying less temperature. With the quicker loss of water, we
obtainmore irregular beads than oven process but with lesser
imperfections on the surface of the beads (see Figure 6).
Analyzing the eﬀect produced by the diﬀerent charac-
teristics of each drying method, we can conclude that the
irregular surface of the beads may be resulted mainly from
the heat energy and the alteration on the shape of the beads
is determined by the water loss rate.
All these characteristics not only are going to influence on
shape and size parameters, but also they are going to aﬀect
the release process [40]. As higher are size parameters we
are going to obtain a quick release rate. In other words, the
use of rotary evaporator as drying method will give rise to a
quicker but less controlled drug release (low t50% with high
AUC).
3.1.5. Diameter Medium. According to ANOVA test, TEA
addition was the most significant contributor factor on par-
ticle size of the beads. As was explained above, the solutions
containing TEA were more viscous. Then, when this polymer
solution was dripped into CaCl2 solution, the gelled beads
presented higher sizes and higher entrapment eﬃciencies [7].
3.2. Determination of Optimal Conditions Using Taguchi
Robust Methodology. The appropriate selection of the pa-
rameters can improve the quality of the product, especially
when at least two quality characteristics are to be simultane-
ously considered. The selection of the response parameters
should account for the objectives of the study and the
feasibility and ease of handling the optimization process [33].
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Figure 6: SEM images of beads dried during: (a) room temperature process (batch 8); (b) oven process (batch 11); (c) rotary evaporator
process (batch 4).
The previous experiments revealed that the selected fac-
tors aﬀected the release profile, the entrapment eﬃciency,
the swelling process, and the morphological and dimen-
sional properties of the beads depending to the analyzed
variable. In the beginning of the optimization process, the
marginal means graph for every response variable at each
level of factors has been determined (Figure 7). Following
these directives, we could select the best combination of
factors and their levels that will give us the best results
for each profile (Table 6).
In order to validate this methodology, the confirmation
tests were performed using their optimal combination of
parameters levels. By using the predicted optimal combi-
nations (Table 7) and a forecasting procedure (using linear
regression) we can evaluate the adequacy of the optimiza-
tions if theirs results are closer to the predicted values.
For every evaluated response and following the combina-
tions obtained by the Taguchi optimization and after confir-
mation tests by triplicate, we could see that predicted results
are inside the confidence intervals obtained by practically all
the optimal batches.
The Taguchi optimization selects the best combination
under conditions that produce consistent performance to
obtain as possible an optimal value. In the Taguchi method,
the robustness of a process is taken into more consideration
than the final value of the optimized response.
The success of the results by applying the Taguchimethod
is partly due to the ability to get good results in formulations
or contexts with high variability. As argued in earlier sections,
this variability is not always controllable by the researcher,
so eﬃcient methods to work in uncertain environments are
always interesting to apply.
Applying the Taguchi method to our results, we demon-
strated that Taguchi method makes the final product less
sensitive to variations than classical optimizations and that
this methodology can be used as a tool for the optimization
of other pharmaceutical forms.
4. Conclusions
In the present work, we have focused on the applicability
of the Taguchi robust methodology in the pharmaceutical
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Figure 7: Marginal means graphs of the S/N ratio for (I) t50%, (II) AUC, (III) EE, (IV) SR, (V) SF, and (VI) Dm. (a): TEA, (b): Carbopol
(% w/v), (c): Flux rate (mL/min), (d): Stirring rate (rpm), (e): Reaction time (min), (f): Drying method, (g): NaCl (% w/v), (h): pH.
field to optimize pharmaceutical processes. A technological
process based on the production of alginate-Carbopol beads
has been selected as an example, taking into account our ex-
perience in that field.
Various formulation variables such stirring rate, flux rate,
reaction time, drying method, and polymer concentration,
and other variables such as NaCl concentration and pH were
selected in the study. The influence of these parameters on
drug entrapment eﬃciency, particle size, surface morphol-
ogy, swelling behavior, and in vitro drug release has been
analyzed.
From the ANOVA tests, it may be concluded that the
drug release rate from the beads was mainly aﬀected by the
Carbopol concentration and the stirring rate of the stirred
during the bead formation process. The alginate-Carbopol
MB-loaded beads had higher swelling percentages in absence
of NaCl in the dissolution medium, and using higher
polymer concentrations and with TEA into the polymeric
solution. Beads dried at ambient conditions showed more
satisfactory sustained release profile.
The Taguchi design method was used to optimize the
parameter values for obtaining the desired characteristics.
Finally, the confirmation tests to verify the model prediction
were carried out and the obtained values were very similar
to the predicted ones. This result reveals the feasibility of
robust optimization. Therefore, this methodology was then
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Table 6: Optimization process carried out in each variable for robust method.
Variable Aim in Taguchi Robust
t50% Smaller is best (to120 minutes) A1B−1C1D0E1F−1G−1H1
AUC Bigger is best A−1B−1C0D0E1F0G0H1
EE Bigger is best A1B0C0D0E1F0G1H−1
SR Bigger is best A1B−1C−1D0E0F0G−1H1
SF Bigger is best A−1B0C1D−1E0F−1G−1H0
Dm Smaller is best A−1B−1C0D−1E0F−1G−1H1
Table 7: Results obtained by confirmation test. SD: standard deviation; CI: confidence interval.
Variable Mean Predicted SD CI (α = 0.05)
t50% 180 186 6.34 180± 7.17
AUC 19359.31 26086.38 613.57 24350.77± 694.3
EE 85.55 87.28 2.32 85.55± 2.62
SR 3073.33 3509.44 122.20 3073.33± 138.28
SF 0.44 0.47 0.10 0.44± 0.06
Dm 1.37 1.55 0.15 1.37± 0.16
validated, being a perfect complement to the classical DOE
methodology in environments with high variability and
noise conditions.
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